JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Ascendis Pharma A-S ADR

Geschlossen

BrancheGesundheitswesen

201.69 0.56

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

200.56

Max

202.41

Schlüsselkennzahlen

By Trading Economics

Einkommen

56M

-39M

Verkäufe

57M

158M

Gewinnspanne

-24.585

Angestellte

1,017

EBITDA

51M

2.3M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+26.88% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

13. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.6B

13B

Vorheriger Eröffnungskurs

201.13

Vorheriger Schlusskurs

201.69

Nachrichtenstimmung

By Acuity

50%

50%

147 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Okt. 2025, 18:41 UTC

Ergebnisse

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24. Okt. 2025, 18:31 UTC

Ergebnisse

Correction to Procter & Gamble to Focus on Innovation

24. Okt. 2025, 16:25 UTC

Wichtige Markttreiber

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24. Okt. 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. Okt. 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24. Okt. 2025, 21:07 UTC

Ergebnisse

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24. Okt. 2025, 20:58 UTC

Ergebnisse

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24. Okt. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24. Okt. 2025, 20:40 UTC

Ergebnisse

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24. Okt. 2025, 20:24 UTC

Ergebnisse

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. Okt. 2025, 20:23 UTC

Ergebnisse

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. Okt. 2025, 20:13 UTC

Ergebnisse

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. Okt. 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24. Okt. 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24. Okt. 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24. Okt. 2025, 19:33 UTC

Ergebnisse

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24. Okt. 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24. Okt. 2025, 18:52 UTC

Ergebnisse

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. Okt. 2025, 18:41 UTC

Ergebnisse

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. Okt. 2025, 18:03 UTC

Ergebnisse

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24. Okt. 2025, 18:02 UTC

Ergebnisse

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24. Okt. 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24. Okt. 2025, 16:57 UTC

Ergebnisse

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24. Okt. 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24. Okt. 2025, 16:44 UTC

Market Talk
Ergebnisse

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24. Okt. 2025, 16:39 UTC

Market Talk
Ergebnisse

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24. Okt. 2025, 16:33 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. Okt. 2025, 16:23 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. Okt. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24. Okt. 2025, 16:07 UTC

Ergebnisse

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Peer-Vergleich

Kursveränderung

Ascendis Pharma A-S ADR Prognose

Kursziel

By TipRanks

26.88% Vorteil

12-Monats-Prognose

Durchschnitt 256.29 USD  26.88%

Hoch 307 USD

Tief 220 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ascendis Pharma A-S ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

17 ratings

17

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

157.66 / 167.29Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Strong Bullish Evidence

Stimmung

By Acuity

147 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat